Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Solid Biosciences Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SLDB
Nasdaq
2834
www.solidbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Solid Biosciences Inc.
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Nov 5th, 2026 6:00 am
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Nov 4th, 2026 2:07 pm
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
- Oct 26th, 2026 6:00 am
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
- Oct 20th, 2026 6:00 am
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct 1st, 2026 2:05 pm
Solid Biosciences to Participate at Upcoming Investor Conferences
- Sep 2nd, 2026 6:00 am
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Aug 6th, 2026 2:08 pm
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
- Jul 1st, 2026 9:28 pm
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
- Jun 18th, 2026 9:04 am
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
- Jun 8th, 2026 1:00 am
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
- Jun 2nd, 2026 5:00 am
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?
- May 20th, 2026 6:36 am
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- May 12th, 2026 2:08 pm
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
- May 7th, 2026 6:00 am
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
- Apr 30th, 2026 6:00 am
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
- Apr 28th, 2026 6:00 am
Scroll